Dorsey 2002.

Methods	Randomized placebo controlled trial Generation of allocation sequence: computer‐generated randomization list Allocation concealment: not mentioned Blinding: participants and study investigators blinded Inclusion of all randomized participants: no (93/122) Length of follow up: 14 days
Participants	Number: 211 children enrolled Inclusion criteria: children 6 months to 5 years old; no history of treatment for malaria in previous 2 weeks or fever in last 48 h; no history of adverse reactions to any of the study drugs; no history of sickle cell disease; haemoglobin 50 g/L or more; willingness to remain in the city of Kampala and follow the study protocol for the next 12 months; parent or guardian written informed consent
Interventions	1. Sulfadoxine‐pyrimethamine (SP) plus amodiaquine (AQ) 2. SP plus artesunate (AS) AQ: 10 mg/kg/day for 2 days and 5 mg/kg for 1 day AS: 4 mg/kg/day for 3 days SP: 25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine; single dose Third arm not relevant to review: SP plus vitamin C placebo
Outcomes	1. Treatment failure at day 14 and 28; at day 28 both adjusted and unadjusted for new infections 2. Mentions adverse events but did not report any 3. Parasite carriage reported for episodes not patients 3. Presence of fever 4. Mentioned adverse events but did not give details by treatment arm
Notes	Location: Mulago Hospital, Kampala, Uganda Date: July 2000 to August 2001 Follow up was 14 days for each episode of malaria over 1‐year period Funding: Fogarty International Center/National Institutes of Health and the UNDP/World Bank/World Health Organization (WHO) Special Programme for Research and Training in Tropical Diseases (TDR)